Bristol-Myers Squibb Says Zenbexus Combination Doubles MRD-Negative Complete Response in Multiple Myeloma Trial

MT Newswires Live09-25 23:10

Bristol-Myers Squibb (BMY) said Friday its Zenbexus treatment combination doubled the rate of minimal residual disease-negative complete response versus the daratumumab, bortezomib, and dexamethasone regimen in a phase 3 trial of relapsed or refractory multiple myeloma.

After a median follow-up of 15.7 months, 41.1% of patients receiving Zenbexus with daratumumab and dexamethasone achieved an MRD-negative complete response rate of 41.1% versus 20.7% for those receiving daratumumab, bortezomib and dexamethasone, the company said.

The overall response rate was 88.9% for the Zenbexus combination compared with 76.1% for the DVd regimen, Bristol-Myers Squibb said.

The trial's other primary endpoint, progression-free survival, remains under evaluation in a confirmatory cohort of 800 patients, the company said.

The US Food and Drug Administration granted accelerated approval in August to Zenbexus combined with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior line of therapy.

Price: 62.19, Change: +0.69, Percent Change: +1.12

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment